ORPHA:401764
Pancytopenia-developmental delay syndrome
Also known as: Trilineage bone marrow failure-developmental delay syndrome
Publications
297
74.6th percentile
Trials
0
Interventional, condition-specific
Researchers
0
Distinct authors in sample
Gene link
ERCC6L2
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare constitutional aplastic anemia characterized by trilineage bone marrow failure (with hypocellularity), with learning disabilities, and microcephaly. Mild facial dysmorphism and have also been reported.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014317
- OMIM:615715
- UMLS:C3810350
Additional Mondo synonyms (2)
bone marrow failure syndrome type 2 · pancytopenia-developmental delay syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — ERCC6L2
- LiteraturePresent
297 matched papers (287 in last 10 years) Source
- Phenotype characterisedPresent
7 HPO annotations (e.g. Cutaneous photosensitivity; Microcephaly; Decreased total leukocyte count) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ERCC6L2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
7
Associated phenotypes · MONDO:0014317
- Cutaneous photosensitivity
- Microcephaly
- Decreased total leukocyte count
- Anemia
- Neonatal hypotonia
Showing 5 of 7 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
297
297 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
297 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
287 in the last 10 years · medium confidence · 74.6th percentile (publications denominator)
Phrase hits: 1 · MeSH hits: 0
Who's working on it?
0
Distinct author names in 1 sampled paper.
Who's working on it?
No author names could be extracted from the sampled publications. Try the Europe PMC query in “How we counted this,” or contact an umbrella rare-disease organisation for researcher referrals.
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN78380445·Recruiting·A clinical trial testing a new treatment called mRNA-4194 for people with Lynch syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42617850·Recruiting·Phase III study of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1-mutated AML
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84044406·No longer recruiting·A Phase I trial of LY3143921 hydrate in solid tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12537955·Not yet recruiting·Comparing a new combination of medicines to the usual intensive chemotherapy treatment given to participants who have been recently diagnosed with acute myeloid leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99654100·No longer recruiting·A first-in-human phase I/II study to evaluate the safety, tolerability, anti-cancer activity and metabolism of SN38-SPL9111 (DEP®-SN38), an SN38 dendrimer conjugate, in patients with advanced solid tumours.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15046526·Recruiting·A platform trial for patients with relapsed malignant mesothelioma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46766641·No longer recruiting·A Phase I randomized, open-label pharmacokinetic comparability study comparing pre- and post-change teclistamab in participants with relapsed/refractory multiple myeloma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57038506·Recruiting·A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of the study drug MYTX-011 in Subjects with Non-Small Cell Lung Cancer Cell Lung Cancer – KisMET-01
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79004846·Recruiting·AL8326 in advanced Small Cell Lung Cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45104480·Recruiting·A modular, multi-part, multi-arm, open-label, phase I/II study to evaluate the safety and tolerability of GRWD5769 alone and in combination with anticancer treatments in patients with solid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10422213·No longer recruiting·A trial to test the use of HIV drugs to treat neurofibromatosis type 2 (NF2) related tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37422164·No longer recruiting·Combination treatment for early hormone-positive HER-positive breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN71474257·Stopped·Comparing a new combination of medicines to the normal standard of care chemotherapy treatment given to patients who have been recently diagnosed with acute myeloid leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10454031·No longer recruiting·A clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune thrombocytopenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17378733·Recruiting·Assessing the use of tailored treatments based on combinations of genes that are active in a tumour, and the impact on outcomes for bladder cancer.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10369994·No longer recruiting·A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of MTL-CEBPA in children with mucopolysaccharidosis type IH
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13185938·No longer recruiting·A study of JNJ-79635322 in participants with relapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11527992·No longer recruiting·A phase 2, open-label, parallel cohort study of subcutaneous amivantamab in multiple regimens in patients with advanced or metastatic solid tumors including EGFR-mutated non-small cell lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27200385·No longer recruiting·A study to assess the safety and distribution of GDC-8264 in combination with standard of care corticosteroid treatment in the blood of participants with high-risk acute graft-versus-host disease (aGVHD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12458940·No longer recruiting·Gene therapy in children with mucopolysaccharidosis II (MPSII) consented below the age of 22 months
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73037722·Recruiting·LION: lifting immune checkpoints with NSAIDs
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13777452·Recruiting·Study of DTP3 in patients with relapsed or refractory multiple myeloma or diffuse large B-cell lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN86607306·No longer recruiting·Pembrolizumab plus chemotherapy for diffuse large B-cell lymphoma that has come back or does not respond to treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN28818784·Recruiting·A randomised trial to investigate whether giving more blood transfusions to people undergoing surgery for hip fracture improves their outcomes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN80103507·No longer recruiting·A clinical trial to see if a mesenchymal stem cells treatment called ORBCEL-C™ can help to treat primary sclerosing cholangitis, rheumatoid arthritis, lupus nephritis and Crohn’s disease
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pancytopenia-developmental delay syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Pancytopenia-developmental delay syndrome" OR "Trilineage bone marrow failure-developmental delay syndrome" OR "bone marrow failure syndrome type 2") OR ("ERCC6L2" OR "ERCC6L2 syndrome" OR "ERCC6L2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pancytopenia-developmental delay syndrome" OR "Trilineage bone marrow failure-developmental delay syndrome" OR "bone marrow failure syndrome type 2"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (297) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-27T15:24:14.283Z
